Long-Term Treatment With rhIGF-1 in GHIS
Launched by IPSEN · Dec 10, 2007
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Height \<-2SD for age and gender
- • IGF-1 \<-2SD for age and gender
- • Evidence of GH resistance
- Exclusion Criteria:
- • closed epiphyses
- • prior active malignancy
- • major organ disfunction
- • treatment with medications that would diminish growth
- • clinically significant cardiac abnormalities
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brisbane, California, United States
Patients applied
Trial Officials
Ipsen Medical Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials